From the publishers of JADPRO

HR+ HER2- Breast Cancer Resource Center

Advertisement

Welcome to the new HR+ HER2- Breast Cancer Resource Center! We’re excited to present you with current information, news items, highlights from the literature, and other resources that focus on this disease space and the advanced practitioner’s role in delivering high-quality care to patients.


Christine McGinn, MSN, APRN, ACNP-BC Oncology Nurse Practitioner Lifespan Cancer Institute	Kate Taucher, PharmD, MHA, BCOP, FASHP, FAPO, FHOPA System Manager, Oncology & Infusion Pharmacy Services PGY2 Oncology Residency Program Director

Clinical Management of Patients Taking Abemaciclib

Endocrine and Targeted Therapy for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer—Capivasertib-Fulvestrant: ASCO Rapid Recommendation Update

HER2 Testing in Breast Cancer - 2023 Guideline Update

Anticancer Research

Risk factors for non-sentinel lymph node metastasis in HR+/HER2- breast cancer with cN0

Radiology Case Reports

Palbociclib and fulvestrant combined regimen induced prolonged bone metastasis control of stage IV HR+/HER2- breast cancer: A case report

Reviews in Cardiovascular Medicine

Risk of cardiovascular events with cyclin-dependent kinases 4 and 6 (CDK 4/6) inhibitors among patients with advanced breast cancer: A systematic review and network meta-analysis

Oncology and Therapy

Palbociclib in HR-positive, HER2-negative advanced/metastatic breast cancer: A systematic scoping review of real-world evidence from countries outside of Western regions that are underrepresented in clinical trials

Journal of Clinical Medicine

Novel treatment strategies for hormone receptor (HR)-positive, HER2-negative metastatic breast cancer

Cancers (Basel)

Social determinants of health and other predictors in initiation of treatment with CDK4/6 inhibitors for HR+/HER2- metastatic breast cancer

Current Opinion in Oncology

Controversies on chemotherapy for early HR+/HER2- breast cancer: The role of anthracyclines and dose intensification

npj Breast Cancer

Impact of dose reductions on adjuvant abemaciclib efficacy for patients with high-risk early breast cancer: analyses from the monarchE study

First-Line Treatment for Metastatic ER+ HER2- Breast Cancer